Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 7Colorectal Neoplasms 5Rectal Neoplasms 4Colonic Neoplasms 3Neoplasm Metastasis 2Gastrointestinal Neoplasms 2Recurrence 1Rcctal Cancer 1Neoplasms 1Metastatic HER2 Positive Gastroesophageal Junction Cancer 1HER2-positive Locally Advanced Resectable Gastric Cancer 1Gastrointestinal Diseases 1Gastric Adenocarcinoma 1Digestive System Diseases 1Carcinoma 1Adenocarcinoma 1Adebrelimab (SHR-1316) 1

Interventions

Cisplatin 12pembrolizumab 11Magnetic Resonance Spectroscopy 11Specimen Handling 10Paclitaxel 6Platinum 5Cyclophosphamide 51,2-diaminocyclohexaneplatinum II citrate 5fludarabine 4durvalumab 4cemiplimab 4Radiotherapy, Intensity-Modulated 4Radiotherapy 3Pemetrexed 3Oxaliplatin 3Nivolumab 3Fluorouracil 3Cetuximab 3Carboplatin 3Biopsy 3poly ICLC 2fludarabine phosphate 2cabozantinib 2atezolizumab 2Radiation 2Ipilimumab 2Interviews as Topic 2Heavy Ion Radiotherapy 2Gemcitabine 2Drug Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma × XELOX × Clear all
NCT05494060 2023-11-07

EXPLORING

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
80 enrolled
Gastrointestinal

Carcinoma, Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡